B R I E F R E P O R T

Viral Load as a Predictor of Outcome in Crimean-Congo Hemorrhagic Fever
1 ϫ 10 P ! .001 1 ϫ 10 copies/mL can be considered to predict a fatal outcome with a positive predictive value of 80%, with 88.9% sensitivity and 92.6% specificity. We suggest that viral load is a measure of the severity of CCHF.
Crimean-Congo hemorrhagic fever (CCHF) is a tick-born disease caused by a Nairovirus of the family Bunyaviridae [1] . Infection is transmitted to humans by Hyalomma ticks or by direct contact with the blood or tissues of infected humans or viremic livestock [2] . CCHF is a potentially fatal disease affecting multiple organ systems and is characterized by extensive ecchymosis, visceral bleeding, and hepatic dysfunction; it has a case-fatality rate of 5.4%-80% [3, 4] .
CCHF has a wide geographic distribution, circulating in Africa, the Middle East, Central Asia, and Central and Southeastern Europe [5] [6] [7] [8] [9] . Patients infected with CCHF virus were first reported in Turkey in 2002 [10] [11] [12] . By the end of 2006, there were 1103 confirmed cases and 59 deaths (a case-fatality rate of 5.4%) in Turkey [4] .
The usual approach for CCHF diagnosis combines the detection of the viral RNA genome and/or the antigen and the detection of specific IgM antibodies in human serum or blood samples. In the acute stage of the illness, serological tests are not suitable for patients who die before humoral immune response. To date, the most rapid and sensitive assay for detection of CCHF virus RNA has been based on RT-PCR for the early stage of infection [13] . This study aimed to determine the association between viral load and the severity of CCHF.
Patients and methods. A prospective study was performed at Ankara Numune Education and Research Hospital, a referral and tertiary-care hospital in Ankara, Turkey, during the spring and summer of 2006. Fifty-one patients who had an epidemiologic risk factor (i.e., a history of tick exposure and/or residence in or travel to an area of CCHF endemicity) and acute febrile syndrome characterized by malaise, bleeding, thrombocytopenia (platelet count, !150,000 platelets/mm 3 ), and elevated aspartate transaminase, alanine transaminase, lactic dehydrogenase, and creatinine phosphokinase levels were referred from surrounding hospitals to the Infectious Diseases and Clinical Microbiology Clinic of Ankara Numune Education and Research Hospital as having a possible case of CCHF. Of these individuals, 36 patients who had PCR results positive for CCHF virus RNA in blood samples were included in the study, and quantitative measurement of CCHF virus was performed daily. TaqMan-based 1-step RT-PCR assay was used for detection and quantification of CCHF virus RNA [13] . The assay was performed in a Perkin-Elmer 7700 Sequence Detection System by using the combination of reverse-transcriptase (MBI Fermentas) and hot start Taq DNA polymerase (Birion GmBH) enzymes. Biochemical and hematological laboratory parameters were measured on a daily basis after admission to the hospital. Previously reported disease-severity criteria were assessed according to viral load [14, 15] . Patients were given preparations of packed RBCs, fresh frozen plasma, and total blood, depending on their homeostatic state. None of the patients received antiviral treatment, because there is currently no specific antiviral therapy for CCHF that is approved for use in humans. In statistical analysis, Student's t test for independent and paired continuous variables and the x 2 test or Fisher's exact test was used, when appropriate, to compare proportions. Results are expressed as if not otherwise indicated. mean ‫ע‬ SD A P value of !.05 was considered to be statistically significant. Stata software, version 9.0 (Stata), was used for the analysis.
Results. During the spring and summer of 2006, 51 patients were hospitalized with possible cases of CCHF. Thirty-six patients had RT-PCR results positive for CCHF virus. In quantitative measurement by RT-PCR, viral loads ranged from copies/mL through у copies/mL. In 10 pa- 3 9 1.1 ϫ 10 9.9 ϫ 10 tients, viral load measurements were obtained that were у copies/mL. Of the 36 patients with positive RT-PCR 9 1 ϫ 10 results, 9 (25%) died. In 8 of the 9 patients with fatal outcomes, viral loads were detected that were у copies/mL; in 25 9 1 ϫ 10 of the 26 patients with nonfatal outcomes, viral loads were detected that were ! copies/mL ( ). The mean 9 1 ϫ 10 P ! .001 peak titer of patients with a fatal outcome was copies/ 9 7.1 ϫ 10 mL, whereas for patients with a nonfatal outcome, the mean titer was copies/mL. 6 4.1 ϫ 10 Of the 92 tested samples that were obtained from the 27 patients with nonfatal outcomes, only 3 samples obtained from 2 (7.4%) of the patients were у copies/mL. Patients 9 1 ϫ 10 with nonfatal outcomes had viral loads between cop-3 1.1 ϫ 10 ies/mL and copies/mL at the time of hospital ad- 8 8.5 ϫ 10 mission, and in 2 patients, viral loads were elevated to 1 copies/mL on the second day of hospitalization. How- 9 1 ϫ 10 ever, more than one-half (16 of 28) of the samples obtained from patients with fatal outcomes that were tested, representing 8 (88.9%) of 9 patients, had viral loads 1 copies/mL. 1 ϫ 10 mL at the time of hospital admission.
In patients with fatal outcomes, the duration of symptoms before hospitalization was shorter than in patients with nonfatal outcomes, but this difference was not statistically significant (mean duration of , days vs. symptoms ‫ע‬ SD 4.8 ‫ע‬ 1.7 6.2 ‫ע‬ days;
). Notably, 8 (88.9%) of the 9 patients with 3.6 P p .257 fatal outcomes had viral loads у copies/mL within the 9 1 ϫ 10 first 4.6 days (range, 2-7 days) after the onset of symptoms, suggesting that a viral load у copies/mL can be con- 9 1 ϫ 10 sidered to predict a fatal outcome with a positive predictive value of 80%, with an 88.9% sensitivity and a 92.6% specificity.
The difference in viral load between the patients with fatal outcomes and those with nonfatal outcomes can be best seen in figure 1 , which shows that the mean viral load for patients with fatal outcomes was у3 log 10 copies/mL higher than the mean viral load for survivors. The epidemiological and clinical characteristics of the patients are presented in table 1. The demographic features of the patients were similar. Physical examination findings revealed that patients with viral loads у copies/mL had a greater frequency of bleeding symp- 9 1 ϫ 10 toms and somnolence than did patients with viral loads ! copies/mL. 9 1 ϫ 10 Almost all of the patients had leuckopenia, thrombocytopenia, and elevated levels of aspartate transaminase, alanine transaminase, lactic dehydrogenase, and creatinine phosphokinase. The patients who had viral loads у copies/mL 9 1 ϫ 10 had lower platelet counts; higher WBC counts; higher aspartate transaminase, alanine transaminase, lactic dehydrogenase, and creatinine phosphokinase levels; longer prothrombin and activated partial thromboplastin time; and higher international normalized ratio and lower fibrinogen levels (table 2 ). An evaluation of previously reported severity criteria according to viral load is presented in table 3.
Discussion. The pathogenesis of CCHF has not been well understood. A common pathogenic feature of viral hemorrhagic fevers is the ability of the etiologic agent to disable the host immune response by attacking and manipulating the cells that initiate the antiviral response [16] . The damage is characterized by marked replication of the virus and immune and vascular dysregulation. Viral hemorrhagic fever viruses infect endothelial cells lining the blood vessels and destroy these vessels [17] . Vascular damage can be induced by immunological mechanisms and/or by direct infection of the vascular tissue. Impairment of endothelial cell function can cause a wide range of vascular effects that lead to changes in vascular permeability or hemorrhage [16] . Endothelial damage would account for the characteristic rash and contribute to hemostatic failure by stimulating platelet aggregation and degranulation with consequent activation of the intrinsic coagulation cascade. Capillary fragility is a common feature of CCHF, suggesting infection of the endothelium [1] . In the present study, the patients with viral loads у copies/mL experienced more-severe dis-9 1 ϫ 10 ease than did patients with viral loads ! copies /mL. We 9 1 ϫ 10 speculate that a high viral load may be associated with greater endothelial damage.
Thrombocytopenia appears to be a consistent feature of CCHF infection, and platelet counts can often be extremely low from an early stage of illness in patients with fatal outcomes [15, 18] . In this study, 80% of the patients with viral loads у copies/mL and 34.6% of the patients with viral loads 9 1 ϫ 10 ! copies/mL had platelet counts р20,000 platelets/mm 3 9 1 ϫ 10 ( ) . P p .015
In previous studies, patients have been defined as having severe disease if they had a leukocyte count у10,000 cells/mm 3 , a platelet count р20,000 platelets/mm 3 , an aspartate transaminase level у200 U/L or у700 U/L, an alanine transaminase level у150 U/L or у900 U/L, an activated partial thromboplastin time у60 s, and/or a fibrinogen level р110 mg/dL during the first 5 days after the onset of illness [14, 15] .
In this study, RT-PCR was used to determine the viral load in multiple samples from patients with CCHF, and these data were correlated with the disease outcome. The patients with viral loads у copies/mL had most of the previously 9 1 ϫ 10 reported severity criteria. Increased CCHF disease severity correlated with high viremia titer.
A marked difference in viral load was previously observed with Ebola virus and Lassa fever virus, for which high levels of viremia, especially early in the course of disease, were associated with poor outcomes [19, 20, 21] . In the present study, one of the striking features is the very high viral loads detected in samples from the patients with fatal outcomes, reaching copies/mL of serum. Viral loads in patients with fatal 9 1 ϫ 10 outcomes were a mean of 3 log 10 higher than viral loads in those patients who survived. The mean peak titer in patients with a fatal outcome was copies/mL, whereas for pa- 9 7.1 ϫ 10 tients with a nonfatal outcome, the mean titer was 6 4.1 ϫ 10 copies/mL. After the onset of symptoms, 88.9% of patients with fatal outcomes had viral loads that reached у copies/ 9 1 ϫ 10 mL within days 2-7, suggesting that a viral load у cop- 9 1 ϫ 10 ies/mL can be considered to predict a fatal outcome with a positive predictive value of 80%, with 88.9% sensitivity and 92.6% specificity. A correct prediction of disease outcome can be correctly assigned 180% of the time if a patient's maximum RNA titer is у copies/mL within 7 days after the onset 9 1 ϫ 10 of symptoms.
In conclusion, we suggest that viral load is a measure of the severity of disease in patients with CCHF. The course of the disease may vary according to the viral load. Measurement of viral load could be an indicator of prognosis.
